GHK-Cu copper peptide claims: separating real data from TikTok hype

What did @lydiaaulozzi_ actually say?

She called topical GHK-Cu copper peptide serum her skin's "secret" for glowiness, crediting it with wound repair, collagen building, and anti-inflammatory effects. She described peptides as molecules that "send signals into the skin" to trigger collagen production and healing. She also positioned the topical serum as a lower-stakes entry point before committing to injectable forms of GHK-Cu, and gave a specific product endorsement for an Asterwood brand serum with hyaluronic acid.

To her credit, she kept her language personal and observational, saying she "really didn't think" it would work and was surprised. That epistemic humility is rare in this corner of TikTok. But several of her mechanistic claims deserve more scrutiny than a 60-second product review can provide.

Does the science back this up?

Partially, yes. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has a legitimate and growing research base, but most of the solid data comes from in vitro studies or injectable/systemic use, not from over-the-counter topical serums.

On the mechanism: she's broadly correct that GHK-Cu acts as a signaling molecule. Research by Pickart and Margolina (2018, Cosmetics) confirms GHK-Cu modulates gene expression tied to collagen synthesis, wound healing, and inflammation. A study by Finkley et al. (2007, Journal of Cosmetic Dermatology) found topical GHK-Cu improved skin density, thickness, and reduced fine lines in a 12-week controlled trial. So the anti-aging and collagen claims are not invented.

The wound repair claim also has support. Murine studies and early human trials suggest GHK-Cu accelerates wound contraction and tissue remodeling (Pickart, 1973, Nature). Anti-inflammatory activity is documented, including inhibition of TNF-alpha and other cytokines (Pickart et al., 2015, Journal of Aging Science).

Where the science gets thinner is bioavailability through intact skin. Penetration of tripeptide-copper complexes through the stratum corneum is concentration and formulation dependent, and most commercial OTC serums have not been tested in clinical trials independently of the ingredient's raw research.

What did they get right and wrong?

She got the core mechanism right. Peptides as signaling molecules is accurate. GHK-Cu does communicate with fibroblasts and keratinocytes to upregulate collagen types I and III. The anti-inflammatory and wound-healing properties are supported in the literature. Framing topical use as a gentler entry point before injectables is also a reasonable and responsible distinction to make.

What she glossed over:

• The leap from "GHK-Cu works" to "this specific OTC serum works" is not supported by published data. Asterwood is not a pharmaceutical-grade formulation, and its bioavailability profile is unknown.
• The "glow" framing is subjective and unmeasurable. Calling it a "secret" makes a cosmetic claim that sounds more like a therapeutic one.
• She doesn't mention that copper peptides can interact with vitamin C serums and reduce efficacy of both. That's a practical omission for anyone building a skincare routine.
• The claim that peptides tell skin to "make more collagen, heal this wound" is directionally accurate but oversimplified. GHK-Cu upregulates specific growth factors including TGF-beta and VEGF, which then mediate those effects. It's not a direct command system.

What should you actually know?

GHK-Cu is one of the better-researched cosmetic peptides. The skepticism wall you should maintain is about product quality, not the ingredient itself. The raw ingredient has real mechanistic data behind it. The commercial serum you buy for $20 on Amazon may or may not contain an effective concentration, may or may not have a formulation that allows dermal penetration, and almost certainly has not been independently tested.

If you want to try topical GHK-Cu, look for formulations with concentrations between 0.1% and 2%, avoid layering immediately with high-concentration vitamin C (ascorbic acid), and understand that results in peer-reviewed trials typically required 8 to 12 weeks of consistent use. The Finkley et al. 2007 trial used a twice-daily application protocol. Seeing "a huge difference" in a shorter window is possible but not what the controlled data shows on average.

The injectable or peptide-therapy version of GHK-Cu is a different conversation entirely, involving different pharmacokinetics, different regulatory considerations, and medical supervision. Do not conflate the two based on a TikTok product review, even a well-intentioned one.